Abstract
In a series of 882 retinoblastoma patients, 384 known to have the genetic form of the disease and 498 others, 30 patients developed second primary neoplasms. The spectrum of these second neoplasms is discussed in relation to the forms of treatment used for the retinoblastoma. Cumulative incidence rates of second tumours in the whole series are 2.0% at 12 years after diagnosis and 4.2% after 18 years. For patients with the genetic form of retinoblastoma the cumulative incidence rate after 18 years is 8.4% for all second neoplasms and 6.0% for osteosarcomas alone. The inherent risk among survivors from genetic retinoblastoma of developing an osteosarcoma, excluding all possible effects of treatment, is estimated to be 2.2% after 18 years. Within the field of radiation treatment the cumulative incidence rate for all second neoplasms after 18 years is 6.6% and for osteosarcomas alone 3.7%. There is some evidence that patients with genetic retinoblastoma are particularly sensitive to the carcinogenic effects of radiation. The results also suggest that the use of cyclophosphamide may increase the risk of second primary neoplasms in patients with genetic retinoblastoma. The incidence rates of second primary neoplasms in retinoblastoma survivors reported here are lower than those quoted for previously published series. Evidence from this and other papers strongly suggests an association between retinoblastoma and malignant melanoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Draper, G., Sanders, B. & Kingston, J. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53, 661–671 (1986). https://doi.org/10.1038/bjc.1986.110
Issue Date:
DOI: https://doi.org/10.1038/bjc.1986.110
This article is cited by
-
Anti-cancer properties of quercetin in osteosarcoma
Cancer Cell International (2021)
-
Radiation dose reduction during intra-arterial chemotherapy for retinoblastoma: a retrospective analysis of 96 consecutive pediatric interventions using five distinct protocols
Pediatric Radiology (2021)
-
Die Rolle von Interleukin-11 beim Osteosarkom
Der Pathologe (2020)
-
Number, frequency and time interval of examinations under anesthesia in bilateral retinoblastoma
Graefe's Archive for Clinical and Experimental Ophthalmology (2020)
-
Trilateral retinoblastoma: A systematic review of 211 cases
Neurosurgical Review (2019)